# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers and the Effect of Itraconazole on CHF10073 Exposure

> **NCT06746064** · PHASE1 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 155 (actual)

## Conditions studied

- Pulmonary Fibrosis

## Interventions

- **DRUG:** CHF10073 (Part 1 - SAD)
- **DRUG:** Placebo (Part 1 - SAD)
- **DRUG:** CHF10073 (Part 2 - MAD)
- **DRUG:** CHF10073 (Part 3)
- **DRUG:** Placebo (Part 2 - MAD)
- **DRUG:** itraconazole (Part 4)
- **DRUG:** CHF10073 (Part 4)

## Key facts

- **NCT ID:** NCT06746064
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-13
- **Primary completion:** 2026-02-04
- **Final completion:** 2026-02-04
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06746064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06746064, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers and the Effect of Itraconazole on CHF10073 Exposure". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06746064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*